UBS Group: Raises Moderna Price Target from $50 to $150

O-3.97%
world+12.72%

BlockBeats News, August 20th, UBS Group announced that it has raised Moderna's (MRNA.O) price target from $50 to $150.

Earlier reports stated that Moderna, in collaboration with Mercedez, has achieved significant success in a Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy to prove effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged by nearly 177% in a single day.

ソース：BlockBeats

免責事項：現在のコンテンツは第三者の視点に基づくもの、または第三者の視点からAIが直接翻訳したものです。CoinExはコンテンツの信頼性、正確性、独創性を保証するものではなく、CoinExからの投資アドバイスを構成するものではありません。暗号資産の価格変動は急激に変動します。潜在的なリスクにご注意ください。